TY - CHAP
T1 - Biomarkers in Psychiatric Drug Development
T2 - From Precision Medicine to Novel Therapeutics
AU - Carreon, Rudy Lozano
AU - Rivas-Grajales, Ana Maria
AU - Murphy, Nicholas
AU - Mathew, Sanjay J.
AU - Jha, Manish K.
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive license to Springer Nature Switzerland AG.
PY - 2023
Y1 - 2023
N2 - Burden of psychiatric disorders is compounded by their wide prevalence as well as the limited efficacy of currently available treatments and the current approaches for prescribing these treatments. The selection of treatments continues to be subjective and often results in a trial-and-error approach. Emerging research suggests that biological markers (or biomarkers) can be used to develop precision medicine approaches for psychiatric disorders. Furthermore, the biomarkers also promise to elucidate the underlying pathophysiological mechanisms which in turn can be used to develop novel therapeutic treatments. In this chapter we have focused on mood disorders and reviewed studies on electroencephalography (EEG), magnetic resonance imaging (MRI), and blood-based biomarkers that can guide selection of one treatment versus another (treatment-selection biomarker) as well as biomarkers that can guide the development of novel therapeutics. These studies suggest that the use of objective physiological data is poised to alter the landscape of psychiatric diagnosis and treatment. However, practical and economic barriers remain as major hurdles. The key to finding such translational diagnostic and therapeutic biomarkers is a better understanding of the underlying pathophysiology, and despite the tremendous advances in neuroscience, it is clear there remains much left to be elucidated.
AB - Burden of psychiatric disorders is compounded by their wide prevalence as well as the limited efficacy of currently available treatments and the current approaches for prescribing these treatments. The selection of treatments continues to be subjective and often results in a trial-and-error approach. Emerging research suggests that biological markers (or biomarkers) can be used to develop precision medicine approaches for psychiatric disorders. Furthermore, the biomarkers also promise to elucidate the underlying pathophysiological mechanisms which in turn can be used to develop novel therapeutic treatments. In this chapter we have focused on mood disorders and reviewed studies on electroencephalography (EEG), magnetic resonance imaging (MRI), and blood-based biomarkers that can guide selection of one treatment versus another (treatment-selection biomarker) as well as biomarkers that can guide the development of novel therapeutics. These studies suggest that the use of objective physiological data is poised to alter the landscape of psychiatric diagnosis and treatment. However, practical and economic barriers remain as major hurdles. The key to finding such translational diagnostic and therapeutic biomarkers is a better understanding of the underlying pathophysiology, and despite the tremendous advances in neuroscience, it is clear there remains much left to be elucidated.
KW - Antidepressant
KW - Biomarker
KW - Neuroimaging
KW - Precision medicine
KW - Psychiatric drug development
UR - http://www.scopus.com/inward/record.url?scp=85150665462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150665462&partnerID=8YFLogxK
U2 - 10.1007/978-3-031-21054-9_12
DO - 10.1007/978-3-031-21054-9_12
M3 - Chapter
C2 - 36928855
AN - SCOPUS:85150665462
T3 - Advances in Neurobiology
SP - 287
EP - 297
BT - Advances in Neurobiology
PB - Springer
ER -